Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

326 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators. Miles D, et al. Among authors: bachelot t. Ann Oncol. 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2. Ann Oncol. 2021. PMID: 34224826 Free article. Clinical Trial.
ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer.
Hurvitz SA, Bachelot T, Bianchini G, Harbeck N, Loi S, Park YH, Prat A, Gilham L, Boulet T, Gochitashvili N, Monturus E, Lambertini C, Nyawira B, Knott A, Restuccia E, Schmid P. Hurvitz SA, et al. Among authors: bachelot t. Future Oncol. 2022 Oct;18(32):3563-3572. doi: 10.2217/fon-2022-0485. Epub 2022 Nov 16. Future Oncol. 2022. PMID: 36382554 Free article.
ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC).
Loibl S, Azim HA Jr, Bachelot T, Berveiller P, Bosch A, Cardonick E, Denkert C, Halaska MJ, Hoeltzenbein M, Johansson ALV, Maggen C, Markert UR, Peccatori F, Poortmans P, Saloustros E, Saura C, Schmid P, Stamatakis E, van den Heuvel-Eibrink M, van Gerwen M, Vandecaveye V, Pentheroudakis G, Curigliano G, Amant F. Loibl S, et al. Among authors: bachelot t. Ann Oncol. 2023 Oct;34(10):849-866. doi: 10.1016/j.annonc.2023.08.001. Epub 2023 Aug 10. Ann Oncol. 2023. PMID: 37572987
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial.
Lin NU, Murthy RK, Abramson V, Anders C, Bachelot T, Bedard PL, Borges V, Cameron D, Carey LA, Chien AJ, Curigliano G, DiGiovanna MP, Gelmon K, Hortobagyi G, Hurvitz SA, Krop I, Loi S, Loibl S, Mueller V, Oliveira M, Paplomata E, Pegram M, Slamon D, Zelnak A, Ramos J, Feng W, Winer E. Lin NU, et al. Among authors: bachelot t. JAMA Oncol. 2023 Feb 1;9(2):197-205. doi: 10.1001/jamaoncol.2022.5610. JAMA Oncol. 2023. PMID: 36454580 Free PMC article. Clinical Trial.
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Loibl S, André F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, Cardoso MJ, Carey LA, Dawood S, Del Mastro L, Denkert C, Fallenberg EM, Francis PA, Gamal-Eldin H, Gelmon K, Geyer CE, Gnant M, Guarneri V, Gupta S, Kim SB, Krug D, Martin M, Meattini I, Morrow M, Janni W, Paluch-Shimon S, Partridge A, Poortmans P, Pusztai L, Regan MM, Sparano J, Spanic T, Swain S, Tjulandin S, Toi M, Trapani D, Tutt A, Xu B, Curigliano G, Harbeck N; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Loibl S, et al. Among authors: bachelot t. Ann Oncol. 2024 Feb;35(2):159-182. doi: 10.1016/j.annonc.2023.11.016. Epub 2023 Dec 13. Ann Oncol. 2024. PMID: 38101773 No abstract available.
Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.
Petit T, Hajjaji N, Antoine EC, Benderra MA, Gozy M, Foa C, Mouysset JL, Grenier J, Mousseau M, Mailliez A, Saghatchian M, Lachaier E, Desmoulins I, Hennequin A, Maes P, Loirat D, Ricci F, Diéras V, Berton D, Tiong FL, Teixeira L, Dohollou N, Lévy C, Bachelot T, Pierga JY. Petit T, et al. Among authors: bachelot t. Cancer Med. 2024 May;13(9):e7168. doi: 10.1002/cam4.7168. Cancer Med. 2024. PMID: 38733172 Free PMC article.
Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trial.
Giacchetti S, Laas E, Bachelot T, Lemonnier J, André F, Cameron D, Bliss J, Chabaud S, Hardy-Bessard AC, Lacroix-Triki M, Canon JL, Debled M, Campone M, Cottu P, Dalenc F, Ballesta A, Penault-Llorca F, Asselain B, Dumas E, Reyal F, Gougis P, Lévi F, Hamy AS. Giacchetti S, et al. Among authors: bachelot t. EBioMedicine. 2024 May 7;104:105141. doi: 10.1016/j.ebiom.2024.105141. Online ahead of print. EBioMedicine. 2024. PMID: 38718683 Free PMC article.
Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohort.
Epaillard N, Lusque A, Jacot W, Mailliez A, Bachelot T, Arnedos M, Le Du F, Brain E, Ferrero JM, Massard V, Desmoulins I, Mouret-Reynier MA, Levy C, Gonçalves A, Leheurteur M, Petit T, Filleron T, Bosquet L, Pistilli B, Frenel JS. Epaillard N, et al. Among authors: bachelot t. ESMO Open. 2024 May 3;9(5):103447. doi: 10.1016/j.esmoop.2024.103447. Online ahead of print. ESMO Open. 2024. PMID: 38703431 Free PMC article.
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial.
Penault-Llorca F, Dalenc F, Chabaud S, Cottu P, Allouache D, Cameron D, Grenier J, Venat Bouvet L, Jegannathen A, Campone M, Debled M, Hardy-Bessard AC, Giacchetti S, Barthelemy P, Kaluzinski L, Mailliez A, Mouret-Reynier MA, Legouffe E, Cayre A, Martinez M, Delbaldo C, Mollon-Grange D, Macaskill EJ, Sephton M, Stefani L, Belgadi B, Winter M, Orfeuvre H, Lacroix-Triki M, Bonnefoi H, Bliss J, Canon JL, Lemonnier J, Andre F, Bachelot T. Penault-Llorca F, et al. Among authors: bachelot t. ESMO Open. 2024 Apr 30;9(5):103443. doi: 10.1016/j.esmoop.2024.103443. Online ahead of print. ESMO Open. 2024. PMID: 38692082 Free PMC article.
326 results